Health
Virus drug benefit only marginal: study – Education – Australian Associated Press
Researchers say a new study of Gilead Sciences’ remdesivir raises questions about the efficacy of the drug in the treatment of COVID-19.
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
General22 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General21 hours agoJaguar Land Rover in UK pauses shipments to US
-
General18 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General17 hours agoAustralian share market set to dive as threat of US recession grows